Blood, tissue, and intracellular concentrations of erythromycin and its metabolite anhydroerythromycin during and after therapy

Antimicrobial Agents and Chemotherapy

Volumn 56, Issue 2, 2012, Pages 1059-1064

  Krasniqi, S ^a   Matzneller, P ^a   Kinzig, M ^b   Sorgel F ^b,c   Huttner S ^b   Lackner, E ^a   Muller M ^a   Zeitlinger, Markus ^a  

^a MEDICAL UNIVERSITY OF VIENNA   (Austria)

^b School of Medicine   (Germany)

^c UNIVERSITY OF DUISBURG ESSEN   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ERYTHROMYCIN; INTESTINE CONTRACTION STIMULATING AGENT;

APPETITE DISORDER; ARTICLE; BODY FLUID COMPARTMENT; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG TISSUE LEVEL; DRUG UPTAKE; HUMAN; HUMAN EXPERIMENT; INJECTION SITE PAIN; INTERSTITIAL FLUID; LEUKOCYTE; LEUKOPENIA; MALE; METEORISM; MINIMUM INHIBITORY CONCENTRATION; NORMAL HUMAN; PRIORITY JOURNAL; SINGLE DRUG DOSE; SOFT TISSUE; STOMACH PAIN; SUBCUTANEOUS FAT; THROMBOCYTOPENIA;

ADIPOSE TISSUE; ADULT; ANTI-BACTERIAL AGENTS; AREA UNDER CURVE; BACTERIAL INFECTIONS; DRUG INTERACTIONS; ERYTHROMYCIN; HUMANS; LEUKOCYTES; MALE; MUSCLES; TISSUE DISTRIBUTION;

EID: 84863419708     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.05490-11     Document Type: Article

References (45)

1. Amsden GW. 1996. Erythromycin, clarithromycin, and azithromycin: are the differences real? Clin. Ther. 18:56-72.
2. Baquero F. 1999. Evolving resistance patterns of Streptococcus pneumoniae: a link with long-acting macrolide consumption? J. Chemother. 11(Suppl 1):35-43. (Pubitemid 29159251)
3. Bergman M, Huikko S, Huovinen P, Paakkari P, Seppala H. 2006. Macrolide and azithromycin use are linked to increased macrolide resistance in Streptococcus pneumoniae. Antimicrob. Agents Chemother. 50:3646-3650. (Pubitemid 44684876)
4. Boggiano BG, Gleeson M. 1976. Gastric acid inactivation of erythromycin stearate in solid dosage forms. J. Pharm. Sci. 65:497-502.
5. Bosnar M, Kelneric Z, Munic V, Erakovic V, Parnham MJ. 2005. Cellular uptake and efflux of azithromycin, erythromycin, clarithromycin, telithromycin, and cethromycin. Antimicrob. Agents Chemother. 49:2372-2377. (Pubitemid 40734469)
6. Carbon C. 1995. Clinical relevance of intracellular and extracellular concentrations of macrolides. Infection 23(Suppl 1):S10-S14.
7. Chaurasia CS, et al. 2007. AAPS-FDA workshop white paper: microdialysis principles, application and regulatory perspectives. Pharm. Res. 24:1014-1025. (Pubitemid 46675390)
8. Craig WA. 2001. Does the dose matter? Clin. Infect. Dis. 33(Suppl 3):S233-S237. (Pubitemid 32835797)
9. Craig WA, Kiem S, Andes DR. 2002. Free drug 24-hr AUC/MIC is the PK/PD target that correlates with in vivo efficacy of macrolides, azalides, ketolides and clindamycin. Abstr. 42nd Intersci. Conf. Antimicrob. Agents Chemother, abstr A-1267.
10. Dette GA, Knothe H. 1986. Kinetics of erythromycin uptake and release by human lymphocytes and polymorphonuclear leucocytes. J. Antimicrob. Chemother. 18:73-82. (Pubitemid 16070371)
11. Foulds G, Shepard RM, Johnson RB. 1990. The pharmacokinetics of azithromycin in human serum and tissues. J. Antimicrob. Chemother. 25(Suppl A):73-82. (Pubitemid 20043952)
12. Friedlander AL, Albert RK. 2010. Chronic macrolide therapy in inflammatory airways diseases. Chest 138:1202-1212.
13. Frimodt-Moller N. 2002. How predictive is PK/PD for antibacterial agents? Int. J. Antimicrob. Agents 19:333-339. (Pubitemid 34326394)
14. Garcia-Rey C, Aguilar L, Baquero F, Casal J, Martin JE. 2002. Pharmacoepidemiological analysis of provincial differences between consumption of macrolides and rates of erythromycin resistance among Streptococcus pyogenes isolates in Spain. J. Clin. Microbiol. 40:2959-2963. (Pubitemid 35284970)
15. Goossens H, Ferech M, Coenen S, Stephens P. 2007. Comparison of outpatient systemic antibacterial use in 2004 in the United States and 27 European countries. Clin. Infect. Dis. 44:1091-1095. (Pubitemid 46580279)
16. Goossens H, Ferech M, Vander Stichele R, Elseviers M. 2005. Outpatient antibiotic use in Europe and association with resistance: a crossnational database study. Lancet 365:579-587. (Pubitemid 40247914)
17. Hansen SL, Swomley P, Drusano G. 1981. Effect of carbon dioxide and pH on susceptibility of Bacteroides fragilis group to erythromycin. Antimicrob. Agents Chemother. 19:335-336. (Pubitemid 11157525)
18. Homma T, et al. 2010. In vitro antibacterial activities of S-013420, a novel bicyclolide, against respiratory tract pathogens. J. Antimicrob. Chemother. 65:1433-1440.
19. Ishiguro M, et al. 1989. Penetration of macrolides into human polymorphonuclear leucocytes. J. Antimicrob. Chemother. 24:719-729. (Pubitemid 20005503)
20. Kibwage IO, et al. 1985. Antibacterial activities of erythromycins A, B, C, and D and some of their derivatives. Antimicrob. Agents Chemother. 28:630-633. (Pubitemid 16215526)
21. Kurath P, Jones PH, Egan RS, Perun TJ. 1971. Acid degradation of erythromycin A and erythromycin B. Experientia 27:362.
22. Lakritz J, Wilson WD, Mihalyi JE. 1999. Comparison of microbiologic and high-performance liquid chromatography assays to determine plasma concentrations, pharmacokinetics, and bioavailability of erythromycin base in plasma of foals after intravenous or intragastric administration. Am. J. Vet. Res. 60:414-419.
23. Malhotra-Kumar S, Lammens C, Coenen S, Van Herck K, Goossens H. 2007. Effect of azithromycin and clarithromycin therapy on pharyngeal carriage of macrolide-resistant streptococci in healthy volunteers: a randomised, double-blind, placebo-controlled study. Lancet 369:482-490. (Pubitemid 46209315)
24. Martin JR, Johnson P, Miller MF. 1985. Uptake, accumulation, and egress of erythromycin by tissue culture cells of human origin. Antimicrob. Agents Chemother. 27:314-319. (Pubitemid 15144691)
25. McCaig LF, Besser RE, Hughes JM. 2003. Antimicrobial drug prescription in ambulatory care settings, United States, 1992-2000. Emerg. Infect. Dis. 9:432-437. (Pubitemid 37070408)
26. Miller MF, et al. 1984. Erythromycin uptake and accumulation by human polymorphonuclear leukocytes and efficacy of erythromycin in killing ingested Legionella pneumophila. J. Infect. Dis. 149:714-718. (Pubitemid 14108373)
27. Mouton JW, Dudley MN, Cars O, Derendorf H, Drusano GL. 2002. Standardization of pharmacokinetic/pharmacodynamic (PK/PD) terminology for anti-infective drugs. Int. J. Antimicrob. Agents 19:355-358. (Pubitemid 34308981)
28. Muller M, et al. 1999. Penetration of ciprofloxacin into the interstitial space of inflamed foot lesions in non-insulin-dependent diabetes mellitus patients. Antimicrob. Agents Chemother. 43:2056-2058. (Pubitemid 29395209)
29. Muller M, et al. 1995. Application of microdialysis to clinical pharmacokinetics in humans. Clin. Pharmacol. Therapeut. 57:371-380.
30. Nibbering PH, Zomerdijk TP, Corsel-Van Tilburg AJ, Van Furth R. 1990. Mean cell volume of human blood leucocytes and resident and activated murine macrophages. J. Immunol. Methods 129:143-145. (Pubitemid 20141330)
31. Petersen I, Hayward AC. 2007. Antibacterial prescribing in primary care. J. Antimicrob. Chemother. 60(Suppl 1):i43-i47.
32. Ryan DM. 1993. Pharmacokinetics of antibiotics in natural and experimental superficial compartments in animals and humans. J. Antimicrob. Chemother. 31(Suppl D):1-16. (Pubitemid 23193749)
33. Salo OP, Gordin A, Brandt H, Antikainen R. 1988. Efficacy and tolerability of erythromycin acistrate and erythromycin stearate in acute skin infections of patients with atopic eczema. J. Antimicrob. Chemother. 21(Suppl D):101-106.
34. Scaglione F, Paraboni L. 2006. Influence of pharmacokinetics/ pharmacodynamics of antibacterials in their dosing regimen selection. Expert Rev. Anti Infect. Ther. 4:479-490. (Pubitemid 43905469)
35. Seppala H, et al. 1997. The effect of changes in the consumption of macrolide antibiotics on erythromycin resistance in group A streptococci in Finland. Finnish Study Group for Antimicrobial Resistance. N. Engl. J. Med. 337:441-446. (Pubitemid 27333044)
36. Stupans I, Sansom LN. 1991. The inhibition of drug oxidation by anhydroerythromycin, an acid degradation product of erythromycin. Biochem. Pharmacol. 42:2085-2090.
37. Traunmuller F, Zeitlinger M, Zeleny P, Muller M, Joukhadar C. 2007. Pharmacokinetics of single- and multiple-dose oral clarithromycin in soft tissues determined by microdialysis. Antimicrob. Agents Chemother. 51:3185-3189. (Pubitemid 350067526)
38. Van Bambeke F, Tulkens PM. 2001. Macrolides: pharmacokinetics and pharmacodynamics. Int. J. Antimicrob. Agents 18(Suppl 1):S17-S23. (Pubitemid 33713498)
39. Wasilewski MM, Wilson MG, Sides GD, Stotka JL. 2000. Comparative efficacy of 5 days of dirithromycin and 7 days of erythromycin in skin and soft tissue infections. J. Antimicrob. Chemother. 46:255-262. (Pubitemid 30639295)
40. WHO. List of essential medicines. World Health Organization, Geneva, Switzerland. http://whqlibdoc.who.int/hq/2011/a95053-eng.pdf.
41. Wiegand RG, Chun AH. 1972. Serum protein binding of erythromycin and erythromycin 2=-propionate ester. J. Pharm. Sci. 61:425-428.
42. Yabe Y, Galetin A, Houston JB. 2011. Kinetic characterization of rat hepatic uptake of 16 actively transported drugs. Drug Metab. Dispos. 39:1808-1814.
43. Zeitlinger M, Muller M, Joukhadar C. 2005. Lung microdialysis-a powerful tool for the determination of exogenous and endogenous compounds in the lower respiratory tract (mini-review). AAPS J. 7:E600-E608.
44. Zeitlinger M, Wagner CC, Heinisch B. 2009. Ketolides-the modern relatives of macrolides: the pharmacokinetic perspective. Clin. Pharmacokinet. 48:23-38.
45. Zeitlinger MA, et al. 2003. Relevance of soft-tissue penetration by levofloxacin for target site bacterial killing in patients with sepsis. Antimicrob. Agents Chemother. 47:3548-3553. (Pubitemid 37345718)